2020

Alzheimer Disease, biomarkers, and clinical symptoms – Quo Vadis?

Auteurs:

Montero-Odasso M*, Ismail Z*, Camicioli R*

Revue:

JAMA Neurology

To the Editor We read with interest the article from Jack et al, and its Editorial that shows that the prevalence of 2 neuropathologic hallmarks of Alzheimer disease (AD), β-amyloid plaques, and neurofibrillary tangles is much higher than the prevalence of 3 associated clinical manifestations: mild cognitive impairment, dementia, and probable AD. Notably, this asymptomatic prevalence of brain load biomarker increased by 3 times in those 85 years and older.

  • Editorial
    The Challenge of Defining Alzheimer Disease Based on Biomarkers in the Absence of Symptoms

Partager

CCNA - CCNV logo

Recevez les
dernières nouvelles

Suivez les derniers développements de la recherche au sein du CCNA-CCNV. Notre section «Nouvelles» fournit des informations sur les études, les avancées et les principaux résultats de la recherche en matière de santé cérébrale.